Robert P. Giugliano

Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial

2017 | 1. lékařská fakulta

Publikace